Innoviva (INVA) Return on Capital Employed (2011 - 2026)
Innoviva (INVA) posted Return on Capital Employed of 11.64% for Q1 2026, down 14.18% on a QoQ basis from 13.57% in Q4 2025, and down 843.0% year-over-year from 1.57% in Q1 2025.
Innoviva (INVA) Return on Capital Employed (2011 - 2026) Analysis & Trends
Innoviva's Return on Capital Employed history runs 16 years deep, the most recent figure standing at 11.64% for Q1 2026.
- Quarterly Return on Capital Employed fell 843.0% year-over-year to 11.64% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 11.64% (down 843.0% YoY) and the FY2025 annual result came in at 11.05%, down 515.0% from the prior year.
- Return on Capital Employed was 11.64% for Q1 2026 at Innoviva, down from 13.57% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 38.14% in Q1 2022 and bottomed at 0.77% in Q2 2023.
- A 5-year average of 12.27% and a median of 13.35% in 2024 frame the typical range for Return on Capital Employed.
- Peak annual rise in Return on Capital Employed reached 2450 bps in 2022, while the deepest fall reached 3969 bps in 2022.
- Innoviva's Return on Capital Employed stood at 1.97% in 2022, then surged by 210 bps to 6.09% in 2023, then soared by 141 bps to 14.66% in 2024, then decreased by 7 bps to 13.57% in 2025, then slipped by 14 bps to 11.64% in 2026.
- Business Quant data shows INVA's Return on Capital Employed at 11.64% in Q1 2026, 13.57% in Q4 2025, and 16.47% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Innoviva | 1.57 Bn | 969.11 Mn | 75.83 Mn | 11.64% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.64% |
| Dec 31, 2025 | 13.57% |
| Sep 30, 2025 | 16.47% |
| Jun 30, 2025 | 19.42% |
| Mar 31, 2025 | 20.07% |
| Dec 31, 2024 | 14.66% |
| Sep 30, 2024 | 13.97% |
| Jun 30, 2024 | 13.35% |
| Mar 31, 2024 | 6.25% |
| Dec 31, 2023 | 6.09% |
| Sep 30, 2023 | 6.01% |
| Jun 30, 2023 | 0.77% |
| Mar 31, 2023 | 1.37% |
| Dec 31, 2022 | 1.97% |
| Sep 30, 2022 | 2.19% |
| Jun 30, 2022 | 22.64% |
| Mar 31, 2022 | 38.14% |
| Dec 31, 2021 | 38.75% |
| Sep 30, 2021 | 41.87% |
| Jun 30, 2021 | 17.42% |